Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Pegaspargase in Advanced ENKTL
NCT04096690Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04096690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096690.